Signature of microRNA dysregulation in spitzoid melanocytic lesions. by Clark, Jennifer
  
 
 
 
 
 
Signature of microRNA dysregulation in spitzoid melanocytic lesions.  
 
A Senior Honors Thesis 
 
 
Presented in Partial Fulfillment of the Requirements for Graduation with distinction in Molecular 
Genetics in the undergraduate colleges of The Ohio State University  
 
By 
  
Jennifer Clark 
 
  
The Ohio State University  
May 2012 
 
 
 
Project Advisors:  
Dr. William Carson III, Department of Surgery 
Dr. Harold Fisk, Department of Molecular Genetics 
 
 
 
  Clark J.R. 
2 
 
Abstract: 
Background: Expression of microRNA has been found to be dysregulated among breast, 
hepatocellular, papillary thyroid, gastric, and colon carcinomas, as well as many other cancers.  
Several studies have used microRNA signatures as biomarkers to determine the diagnosis and 
prognosis of patient tumors.  Although several studies have identified dysregulated microRNAs 
in malignant melanoma, dysregulated microRNAs in spitzoid melanocytic lesions have yet to be 
investigated.  The purpose of this study is to develop a microRNA signature to be used in 
determining the diagnoses and prognoses of spitzoid melanocytic lesions.   
Methods: A literature review was conducted to collate a list of microRNAs that were found to 
have significant dysregulation in primary malignant melanomas.  The expression of the 
microRNAs was quantified by qPCR in benign nevi (n=10), benign Spitz tumors (n=8), atypical 
Spitz tumors (n=12), and spitzoid melanomas (n=4) tissue samples, using RNU48 (housekeeping 
snRNA) as an internal control.   
Results: Nine microRNAs were found to be differentially expressed between the tissue types.  
For example, let-7a, miR-22, miR-125b, and miR-148b were found to be dysregulated in spitzoid 
melanomas when compared to benign Spitz tumors.  The expression of let-7a, miR-125b, 
miR-148b, and miR-211 exhibited general trends across the tissue types as the architectural and 
cytological characteristics of malignancy increased.   
Conclusion: These results may develop a specific microRNA signature that could distinguish 
one tissue type from another tissue type in a patient sample.   Future studies will also include 
applying the signature to patient samples, verifying it with previously established 
histopathological methods, and following individual patient outcomes. 
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Introduction 
Malignant melanoma is considered the most aggressive type of skin cancer.  Melanoma 
has the fastest rising global incidence of any malignancy, as its incidence has doubled in the past 
20 years
1,2
.  Melanocytes, which are pigmented cells present in the basal layer of the epidermis, 
give rise to the malignant cells of melanoma after malignant transformation
3
.  Although only 4% 
of all skin cancers are diagnosed as melanoma, it accounts for 74% of skin cancer deaths
4
.  Early 
identification of a primary lesion as melanoma is critical. There is a 90% chance of survival 
when melanoma is diagnosed at stage I. However, the five-year survival rate decreases to 60% 
when it is diagnosed at stage II and then 10% at stage III.  The steady decrease of survival rate 
following delayed diagnosis reflects a lack of effective treatments as the disease progresses
5
.  
Recently, studies have investigated the importance of molecular markers, including 
microRNA, in the diagnosis of melanoma
8
.  MicroRNAs (miRs) are a class of small non-coding 
RNAs that measure 21-23 nucleotides in length
9
.  MicroRNAs act to negatively regulate gene 
expression at the post-transcriptional level, blocking other RNA transcripts from being processed 
into their respective proteins
5,8
. The precursor to the microRNA is the pre-microRNA, which is 
transcribed by RNA Polymerase II.  The pre-microRNA goes through normal 
post-transcriptional processing, including adenylation and capping.  Before exiting the nucleus, it 
is cut to approximately 70 nucleotides in length by the RNAse III enzyme Drosha
5
.  This 
precursor is exported out of the nucleus by the Ran-GTP-dependent nuclear export factor, 
exportin-5.  It is then processed and cut by the RNase III endonuclease, Dicer, releasing a 
double-stranded mature microRNA strand.  The microRNA is then incorporated into the 
RNA-induced silencing complex (RISC).  However, only one strand of the microRNA remains 
stable enough to partially base complement with the 3’ untranslated region (UTR) of the target 
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mRNA.  The strand that is not functional, called the passenger strand, plays a role comparable to 
the guide strand functioning in the RISC complex
10
.  The microRNA-RISC-mRNA association 
blocks the translation machinery from processing the mRNA into a protein and/or causes mRNA 
degradation, therefore silencing the mRNA
5
.  This association ultimately results in the 
downregulation of the overall expression of microRNA target genes. 
There are 721 identified microRNAs in the human genome that regulate approximately 
30% of human genes
12
.  MicroRNAs regulate mRNA targets that function in cellular 
differentiation, cell-cycle control, apoptosis, cell proliferation, and cell adhesion
5,7,10,13
. These 
processes are often altered in cancer development and progression, thereby implicating 
microRNA dysregulation in cancer pathogenesis
5,7,8,10,12,13,14,15,16,17,18,19,20, 21,22,23,24
.  Fifty percent 
of microRNA genes have been located in cancer-associated genomic regions
15
.  Consequently, 
microRNAs have received attention as potential biomarkers to be used as diagnostic and 
prognostic markers in cancer
8,10,12,25,26,27
.  One method of applying this clincopathological 
potential is to develop a microRNA signature, a unique pattern of dysregulated microRNAs, 
specific to a type of cancer.  The microRNA signature could then be compared to the microRNA 
pattern of a patient’s lesion in order to determine an accurate classification of the tumor and its 
possible outcome
10
. 
MicroRNA signatures specific to some cancers have previously been investigated.  These 
cancers include breast
28,29,30
, hepatocellular
32
, papillary thyroid
33
, gastric and colon
35,36,37,38
 
carcinomas, as well as primary glioblastoma
31
, endocrine tumors
10,33,39
, lung
30,34
, esophageal
40
, 
pancreatic
41
, and kidney
42
 cancers.  Several studies have applied microRNA signatures to 
determine the diagnosis and prognosis of patient tumors.  MicroRNA signatures have been used 
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to determine prognoses in lung
43
 and breast cancers
44
 and diagnoses in kidney
45
 and uterine 
carcinomas
46
.   
Several studies have also investigated the correlation between microRNA dysregulation 
and melanoma.  Using real time polymerase chain reaction (qPCR), Satzger et al. identified 
miR-34a, miR-210, and miR-15b to be significantly dysregulated in primary melanoma tumors 
as compared to melanocytic nevi
99
.  Philippidou et al. performed a microRNA microarray and 
found miR-23b, miR-125b, miR-148b, miR-150, miR-155, miR-200c, let-7a, and 23 other 
microRNAs to be significantly dysregulated in primary melanoma tumors as compared to benign 
nevi.  These results were verified by qPCR
12
.  Mueller et al. performed a microarray to find 
miR-17-5p, miR-148b, and 3 other microRNAs, to be significantly dysregulated in primary 
melanoma, which were also confirmed by qPCR
5
.  Using microRNA microarray with qPCR 
verification, Segura et al. found miR-150 and miR-155 to be significantly dysregulated in 20 
primary melanomas
8
.  As a result, there is a great deal of interest in the potential diagnostic and 
prognostic uses of applying microRNA signatures to patient tissue samples by comparative 
means
,8,10,12,25,26,27
.  These and several other publications were used in this study for the purpose 
of assembling a list of prominently dysregulated microRNAs in melanoma that was then studied 
in various melanocytic lesions.  
Primary melanocytic lesions can be classified into several categories, including benign 
nevi, benign Spitz tumors, atypical Spitz tumors, and spitzoid melanomas.  There are a number 
of gross and microscopic features (architectural and cytologic features) specific to each 
pathological type that contribute to the classification of a lesion.  However, many patient lesions 
have a combination of features from more than one category or have a feature that exists outside 
the delineated categories.  Therefore, the practical application of assigning these features in 
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spitzoid melanocytic lesions allows for subjectivity and error within a histopathological gray 
area
6,7
.  Since the diagnosis of the lesion determines the aggressiveness of treatment necessary 
and the prognosis, it is imperative that the most accurate classification is made.  A false-negative 
diagnosis could result in less treatment than necessary and could negatively impact the survival 
of the patient.  Conversely, a false-positive diagnosis could result in unnecessary morbidity from 
surgery or adjuvant therapy for the patient
7
. 
This study involved the investigation of the microRNA signatures of four types of 
melanocytic lesions: benign nevi, benign Spitz tumors, atypical Spitz tumors, and spitzoid 
melanomas.  Benign nevi are hyper-pigmented epithelial lesions that do not demonstrate any 
signs of malignancy at its current state.  Benign Spitz tumors are benign tissue lesions that are 
composed of large spindled or epithelioid melanocytes that commonly develop in the first two 
decades of life.  Spitzoid melanomas are malignant melanocytic lesions that have various 
architectural and cytologic attributes overlapping those of a benign Spitz tumor. Atypical Spitz 
tumors, which are sometimes categorized as borderline melanocytic lesions, belong to a 
diagnostic category that is less defined.  Generally this tissue type includes lesions that have 
architectural and cytologic characteristics intermediate between benign Spitz tumors and spitzoid 
melanomas.  Characteristics that indicate malignancy include displaying architectural atypicality, 
such as a lack of circumscription or observable maturation defects, and/or cytologic atypicality, 
such as a high number of cells in mitosis
6
.  In this study, the candidate microRNAs were selected 
from a literature review and measured in each tissue type by qPCR to determine a microRNA 
signature for these spitzoid melanocytic lesions.  Attaining differential microRNA expression 
between the tissue types would allow for comparative analysis and provide possible diagnostic 
tools for these spitzoid melanocytic lesions. 
Materials and Methods 
A Literature Review was conducted to determine a list of prominently dysregulated 
microRNAs that are suspected to influence the development of primary malignant melanoma.  
Nine scientific publications that focused on the presence of dysregulated microRNA in primary 
melanoma tissue samples were used in the collation of the list.  The authors of these nine 
publications include: Grignol et al.
7
, Mueller et al.
5
, Mazar et al.
100
, Penna et al.
102
, Philippidou 
et al.
12
, Satzger et al.
99
, Segura et al.
8
, Schultz et al.
103
, and Jukic et al.
101
. Within these 
publications, the dysregulation of microRNAs in primary melanoma tissue samples was verified 
by qPCR.  From these experiments, microRNAs were considered to be significantly dysregulated 
if they demonstrated a greater than 2-fold change.  If the microRNA was verified to be 
dysregulated in more than one publication, it was considered for the list of potential microRNAs 
to investigate.  Final discernment of which microRNA was to be included was indicated by the 
number of times the microRNA was confirmed by the other articles.  The list was completed 
with twelve microRNAs that were suspected to influence the development of primary malignant 
melanoma.  The twelve microRNAs (miRs) include: let-7a, miR-17-5p, miR-21, miR-22, 
miR-23b, miR-34a, miR-125b, miR-148b, miR-150, miR-155, miR-200c, and miR-211. 
 
Dermatological Tissue Samples of four different categories of melanocytic lesions were 
requested for this study.  These tissue types consisted of benign nevi, benign Spitz tumors, 
atypical Spitz tumors, and spitzoid melanomas.  These samples were identified as such by Dr. 
Sara Peters, a dermatopathologist at The Wexner Medical Center at the Ohio State University.  
The tissues were obtained from the Wexner Medical Center (IRB no. 2007 C0015).  The tissues 
were requested and received from the Ohio State University Tissue Archive Service as four to 
ten formalin-fixed, paraffin-embedded tissue column strips of 10-20 microns each.  Ten benign 
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nevi, eight benign Spitz tumors, twelve atypical Spitz tumors, and four spitzoid melanomas were 
used for this study. 
 
RNA Extraction was performed on the 10-20 micron formalin-fixed, paraffin-embedded (FFPE) 
tissue samples.  RecoverAll Total Nucleic Acid Isolation Kit for FFPE was used to harvest total 
RNA per the manufacturer’s recommendations (Ambion, Foster City, CA, USA).  One milliliter 
of 100% xylene was added to four 10-20 micron FFPE curls to dissolve the paraffin surrounding 
the tissue.  The sample was then incubated at 50°C for 3 minutes, vortexed, and centrifuged.  
Since xylene is a carcinogenic substance, after xylene was decanted, 100% ethanol was used to 
dilute the xylene in a safe manner, and any remnant of either liquid was evaporated. Following 
this, Ambion’s protease and digestion buffer was added to the sample and incubated at 50°C for 
15 minutes, then subsequently at 80°C for 15 minutes to safely rid the sample of protein.  
Isolation additive mix, which included absolute ethanol, was added to the sample.  This was 
followed by multiple washes, which was used to isolate the nucleic acids while being passed 
through a filter cartridge.  Sixty microliters of DNase mix, consisting of DNase and 10X DNase 
buffer, was added to the sample to destroy any remaining DNA residues and then incubated for 
30 minutes at room temperature.  Again, multiple washes were used to purify and stabilize the 
RNA molecules in each sample.  Thirty microliters of nuclease-free water was added to elute the 
RNA product through a filter cartridge.  The RNA was then stored at -80°C. 
 
Nano-Drop Quantification was performed to determine the relative concentration and quality 
of RNA using a BioTek Epoch microplate spectrophotometer.  The computer program used to 
process the data was BioTek’s Gen5 1.11. RNA quality was determined by the wavelength 
260/280 ratio of approximately 2.  This ratio indicates the relative RNA to protein content, 
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respectively, and allows for purity determination.  The concentration was calculated in 
nanograms per microliter and a minimum of 10 ng/µl was needed to perform the qPCR reactions 
with each sample.   
 
Quantitative PCR was performed to measure the amount of microRNA in each dermatological 
tissue sample.  The microRNAs measured were chosen from the methods described in the 
literature review section
5,7,8,12,99,100,101,102,103
.  MicroRNA-specific primer probes were used.  All 
reagents and primer probes were obtained from Applied Biosystems (Foster City, CA, USA).  
Reverse transcription reactions and qPCR was performed by the Nucleic Acid Shared Resource 
(NASR) at the Wexner Medical Center James Comprehensive Cancer Center. The NASR utilizes 
the  Fast TaqMan Chemistries as directed by Applied Biosystems.  Applied Biosystems TaqMan 
Fast Advanced Master Mix is the key regulator in this experimental process which uses Optical 
Fast 96-Well Plates.  Each microRNA quantity was normalized to a small nucleolar 
“housekeeping” RNA, RNU48, as a control.  Gene expression levels were quantified using the 
ABI Prism 7900HT Sequence Detection System (Applied Biosystems).  Comparative qPCR, 
using the delta CT method, was performed in triplicate. MicroRNA expression was calculated as 
2
(-∆CT)
 relative to the internal control RNU48
104
. 
 
Statistical Analysis was performed using an unpaired two sample Student’s t-test to compare the 
2
(-∆CT) 
for each tissue type.  A threshold of p<0.05 was utilized to determine statistically 
significant differences between the groups tested.  MicroRNA fold change expression differences 
between tissue types were calculated by dividing the 2
(-∆CT)
 value of one type of tissue by the 
2
(-∆CT)
 value of the comparing tissue.  If statistically significant, fold change in expression is 
expected to be above 2.0-fold when using a two sample t-test. 
Results 
Literature review identified twelve candidate microRNAs to further investigate.  A list of 
microRNA candidates was selected, following an extensive literature review, for the purpose of 
investigating a microRNA signature of spitzoid melanocytic lesions.  Several criteria had to be 
met in order for the publication to be considered applicable to the literature review.  Melanoma 
cell lines were determined not to be a reliable source of data due to their high variability and 
unclear clinical application to actual patients.  The environment in which a cell line exists is 
chemically and biologically different than the environment of a cell within the epithelial layer of 
a patient tissue sample, and therefore, possible developmental differences could result.  Data 
from studies that used patient tissue samples may translate more appropriately to clinical use.  
Therefore, only publications that studied expression levels of microRNA in primary melanoma 
tissues were considered for the literature review. 
Another criterion for a paper to be considered applicable for the literature review was the 
use of qPCR in the attainment of data.  Results from the qPCR analysis had to exhibit a 2.0-fold 
difference of microRNA expression levels in primary melanomas when compared to that of 
benign nevi.  Another commonly used method to determine differential expression of microRNA 
is microarray.  Although a microarray shows differential microRNA expression, it does not show 
the degree to which the microRNA is dysregulated, and the difference in expression may not be 
statistically significant.  Therefore, it was determined that the use of microarray could not be a 
valid method of determining dysregulated microRNA expression without confirmation by qPCR.  
Furthermore, in order for a microRNA to be considered a candidate for this investigation, the 
microRNA needed to show consistent results in multiple publications. 
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The criteria narrowed the literature review to nine publications by Grignol et al
7
, Mueller 
et al.
5
, Mazar et al.
100
, Penna et al.
102
, Philippidou et al.
12
, Satzger et al.
99
, Segura et al.
8
, Schultz 
et al.
103
,and Jukic et al.
101
.  From these nine publications, twelve microRNAs were shown to 
have consistently dysregulated expression in melanoma as compared to benign nevi.  These five 
microRNAs were upregulated in melanoma as compared to benign nevi: miR-17-5p, miR-21, 
miR-22, miR-150,
 
and miR-155
5,7,8,12,101
.  These seven microRNAs were downregulated in 
melanoma as compared to benign nevi: miR-23b, miR-34a, miR-125b, miR-148b, miR-200c, 
miR-21, and let-7a
5,12,17,99,100,101,103
.  Upregulation is defined by increased levels of expression 
seen in a tissue type as compared to the level of expression observed in benign nevi.  
Downregulation is defined by decreased levels of expression seen in a tissue type as compared to 
the level of expression observed in benign nevi. 
Several microRNAs were found to be differently expressed in the four tissue types.  Total 
RNA was extracted from formalin-fixed, paraffin-embedded patient samples, including ten 
benign nevi, eight benign Spitz tumors, twelve atypical Spitz tumors, and four spitzoid 
melanomas.  qPCR was used to measure the expression of each microRNA in each tissue type 
(See Figure 1). A small nucleolar RNA, RNU48, was used as a control, and the measured 
candidate microRNAs were normalized to the expression of RNU48.  The delta CT method was 
used, allowing for fold change to be evaluated by the formula, 2
(-∆CT) 104
.  The expression levels 
were then compared between each tissue type by a two sample t-test comparing the values of 
2
(-∆CT)
.  To be determined statistically significant, the two sample t-test calculation had to 
represent p<0.05.  This indicates a less than a 5% possibility that these results are due to chance 
alone.  
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MiR-22, miR-23b, miR-34a, miR-125b, and miR-150 were found to be dysregulated in 
benign Spitz tumors when compared to benign nevi.  The comparison of benign Spitz tumors 
to benign nevi revealed five microRNAs to be significantly dysregulated: miR-22, miR-23b, 
miR-34a, miR-125b, and miR-150.  The microRNAs that were found to be upregulated in benign 
Spitz tumors as compared to benign nevi were miR-22 by 5.9-fold (p=0.04), miR-23b by 
4.4-fold (p=0.01), miR-34a by 4.8-fold (p=0.03), and mir-150 by 6.0-fold (p=0.03).  The 
microRNA that was found to be downregulated in benign Spitz tumors as compared to benign 
nevi was miR-125b by 2.1-fold (p=0.05).  (See Table 1).  The differential expression of let-7a, 
miR-17-5p, miR-21, miR-148b, miR-155, miR-200c, and miR-211 were not found to be 
statistically significant, indicating similar expressions between the comparable tissue types.  
However, none of them were uniquely similar between only these benign samples. 
Let-7a, miR-22, miR-34a, miR-125b, miR-148b, miR-155 were found to be dysregulated in 
spitzoid melanomas when compared to benign nevi.  When comparing the microRNA 
expressions of benign nevi and spitzoid melanomas, there were six microRNAs that were found 
to be significantly dysregulated in spitzoid melanoma: let-7a, miR-22, miR-34a, miR-125b, 
miR-148b, miR-155.  The microRNAs that were found to be upregulated in spitzoid melanomas 
as compared to benign nevi were miR-22 by 20.9-fold (p=0.0001), miR-34a by 11.3-fold 
(p=0.0002), miR-148b by 76.2-fold (p=0.0002), and miR-155 by 13.1-fold (p=0.0001).  The 
microRNAs that were found to be downregulated in spitzoid melanomas as compared to benign 
nevi were let-7a by 26.6-fold (p=0.01) and miR-125b by 310.0-fold (p=0.008). (See Table 2.) 
Let-7a, miR-22, miR-125b, and miR-148b were found to be dysregulated in spitzoid 
melanomas when compared to benign Spitz tumors.  The comparison of spitzoid melanomas 
to benign Spitz tumors revealed four microRNAs to be significantly dysregulated: let-7a, 
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miR-22, miR-125b, and miR-148b.   The microRNAs that were found to be upregulated in 
spitzoid melanomas as compared to benign Spitz tumors were miR-22 by 3.5-fold (p=0.02) and 
mir-148b by 40.4-fold (p=0.001).  The microRNAs that were found to be downregulated in 
spitzoid melanomas as compared to benign Spitz tumors were let-7a by 47.3-fold (p=0.05) and 
miR-125b by 147.0-fold (p=0.03).  (See Table 3). 
MiR-23b, miR-125b, and miR-155 were found to be dysregulated in atypical Spitz tumors 
when compared to benign nevi. The comparison of atypical Spitz tumors to benign nevi 
revealed three microRNAs to be significantly dysregulated: miR-23b, miR-125b, and miR-211.  
The microRNA that was found to be upregulated in atypical Spitz tumors as compared to benign 
nevi was miR-23b by 3.5-fold (p=0.008).  The microRNAs that were found to be downregulated 
in atypical Spitz tumors as compared to benign nevi were miR-125b by 3.2-fold (p=0.002) and 
miR-211 by 6.0-fold (p=0.01).  (See Table 4). 
MiR-150 was found to be dysregulated in atypical Spitz tumors when compared to benign 
Spitz tumors.  The comparison of benign Spitz tumors and atypical Spitz tumors demonstrated 
that miR-150 was under-expressed by 3.7-fold in atypical Spitz tumors (p=0.04).  (See Table 5).    
Let-7a, miR-22, miR-34a, miR-125b, miR-148b, and miR-155 were found to be 
dysregulated in spitzoid melanomas when compared to atypical Spitz tumors.  The 
comparison of spitzoid melanomas to atypical Spitz tumors revealed seven microRNAs to be 
significantly dysregulated: let-7a, miR-22, miR-34a, miR-125b, and miR-148b, and miR-155.  
The microRNAs that were found to be upregulated in spitzoid melanomas as compared to 
atypical Spitz tumors were miR-22 by 12.9-fold (p=0.00004), miR-34a by 5.5-fold (p=0.0005), 
miR-148b by 92.8-fold (p=0.00005), and miR-155 by 3.2-fold (p=0.03).  The microRNAs that 
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were found to be downregulated in spitzoid melanomas as compared to atypical Spitz tumors 
were let-7a by 28.0-fold (p=0.02) and miR-125b by 3.2-fold (p=0.02).  (See Table 6).  The 
expressions of miR-17-5p, miR-21, and miR-200c were not found to be statistically different in 
any tissue type comparison. 
 
The expression levels of miR-125b, miR-148b, miR-211, and let-7a have exhibited general 
trends across the tissue types.  There are general trends following the expression of particular 
microRNAs within the tissue type.  MiR-125b is shown to be downregulated as the tissue 
samples have more architectural and cytologic characteristics of malignancy.  The fold change as 
normalized to RNU48 is as follows: 3.2 ±1.9 in benign nevi, 1.5 ± 1.1 in benign Spitz tumors, 
0.99 ±0.75 in atypical Spitz tumors, and 0.010±0.010 in spitzoid melanomas.  Each expression 
comparison was found to be statistically significant except the fold change of expression in 
atypical Spitz tumors as compared to benign Spitz tumors.  MiR-125b was found to be 
significantly under-expressed in spitzoid melanomas when compared to benign nevi (p=0.008), 
benign Spitz tumors (p=0.03), and atypical Spitz tumors (p=0.02).  MiR-125b was also 
downregulated in benign Spitz tumors when compared to benign nevi (p=0.05), and in atypical 
Spitz tumors when compared to benign nevi (p=0.002).  Also, every comparison of expression 
was found to be above 2.0-fold except for the comparison of the atypical Spitz tumors to benign 
Spitz tumors.  (See Figure 2G). 
MiR-148b was found to be upregulated in spitzoid melanomas with an expression of 
0.71±0.456, normalized to RNU48.  Conversely, miR-148b showed very small expression levels 
when normalized to RNU48 in benign nevi, benign Spitz tumors, and atypical Spitz tumors, 
(0.0093±0.0082, 0.018±0.016, 0.0077±0.0066, respectively).  MiR-148b was significantly 
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over-expressed in spitzoid melanomas when compared to benign nevi (p=0.0002), benign Spitz 
tumors (p=0.002), and atypical Spitz tumors (p=0.00005).  (See Figure 2H). 
MiR-211 was observed to be upregulated in benign nevi tissue in comparison to other 
tissue types with the expression of 3.6±3.7, normalized to RNU48.  Benign Spitz tumors, 
atypical Spitz tumors, and spitzoid melanomas have exhibited expression levels lower than 
benign nevi at 1.2±1.4, 0.6±0.6, and 1.1±0.80, respectively.  However, the only statistically 
significant upregulation of miR-211 was found in benign nevi when compared to atypical Spitz 
tumors (p=0.01).  (See Figure 2L.) 
Let-7a was found to be downregulated as the architectural and cytologic characteristics of 
malignancy increase within the tissue spectrum of benign Spitz tumors, atypical Spitz tumors, 
and spitzoid melanomas.  Let-7a expression in benign Spitz tumors, atypical Spitz tumors, and 
spitzoid melanomas were found to be 2.1±1.8, 1.2±0.89, 0.044±0.051, respectively.  All fold 
changes were found to be statistically significant when let-7a expression in benign nevi 
(p=0.01), benign Spitz tumors (p=0.5), atypical Spitz tumors (p=0.02), was compared to 
spitzoid melanomas.  (See Figure 2A). 
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Discussion 
This study was conducted to determine a microRNA signature of spitzoid melanocytic 
lesions.  A list of candidate microRNAs was collected following a literature review, and the 
microRNA expression levels were measured by qPCR from formalin-fixed, paraffin-embedded 
tissue patient samples.  A number of microRNAs were found to have significantly different 
expression patterns among the following types of skin lesions:  benign nevi, benign Spitz tumors, 
atypical Spitz tumors, and spitzoid melanomas.  Analysis was conducted according to the 
expression pattern of each tissue type comparison.   
From analysis of the qPCR data, it was observed that several microRNAs exhibited 
trends of differential expression.  For instance, miR-125b gradually decreased in expression as 
the tissue type increased in architectural and cytological characteristics of malignancy.  
MiR-125b expression was found to be significantly different in every tissue type comparison, 
with the exception of atypical Spitz tumors compared to benign Spitz tumors.  Philippidou et 
al.
12
 found miR-125b to be downregulated in 17 primary malignant melanomas.  MiR-125b is 
also found to be significantly dysregulated in endometrial
47,48
, cervical
49,50
, breast
28,51,52
, 
prostate
53,54
, thyroid
57
, ovarian
58,59
, colorectal
60
, and bladder
61,62 
cancers as well as leukemia
55,56
.    
Amongst the many targets of miR-125b, a prominent and well-studied target is the BCL-2, whose 
respective protein, Bcl-2, functions in apoptosis through the mitochondrial pathway
59,63,64,65,66
.  
Another target includes MAZ, whose respective protein is a Myc-associated Zinc finger 
transcription factor for a gene that promotes tumor-associated angiogenesis, VEGF
67
.  One other 
target is BMF, whose respective protein is a bcl-2 modifying factor
68
.  In addition, miR-125b was 
also found to regulate ARID3B, whose protein functions in the motility of breast cancer cells
69
.  
The downregulation of miR-125b in spitzoid melanomas would, therefore, likely result in 
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increased translation of BCL-2, MAZ, BMF, and ARID3B.  This suggests that the effects of 
dysregulated miR-125b are not specific to a particular type of cancer, but are a part of the general 
processes that lead to cancer.  
This investigation also showed that miR-148b was significantly upregulated in spitzoid 
melanomas when compared to the expression levels of benign nevi, benign Spitz tumors, and 
atypical Spitz tumors.  However, Philippidou et al.
 12
 and Mueller et al.
 5
 found miR-148b to be 
downregulated in primary melanoma tumors.  MiR-148b has also been found to be dysregulated 
in other cancers, including ovarian
70
, colorectal
71
, oral
72
, gastric
73
, and esophageal
74 
cancers.   In 
gastric and colorectal cancers, miR-148b is known to target a mRNA of a cholecystokinin-B 
receptor, which is active during digestion
71,73
.  The upregulation of miR-148b in spitzoid 
melanomas would likely result in the downregulated translation of the mRNA of a 
cholecystokinin-B receptor.  MiR-148b is also known to cause aberrant glycosylation in IgA 
nephropathy via C1GALT1
74
.  MiR-148b may play different roles depending on the type of cell it 
functions in.  This study’s results of miR-148b upregulation in spitzoid melanomas differed from 
previous studies’ results that showed downregulation of miR-148b in primary melanomas.  This 
disagreement may be because this study looked at only the spitzoid type of melanoma and not all 
types of melanoma.  
Another microRNA that exhibited differential expression was miR-211, which was 
upregulated in benign nevi.  However, only the expression comparison of benign nevi to atypical 
Spitz tumors was found to be statistically significant.  Jukic et al.
 101
, Mazar et al.
 100
, and 
Grignol et al.
 7
 found miR-211 to be downregulated in primary melanoma as compared to benign 
nevi.  MiR-211 is found to be upregulated in colorectal cancer, and it acts by suppressing 
translation of CHD5 to its respective protein, a chromodomain-helicase DNA binding protein 
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and an identified tumor-suppressor.  When the expression of miR-211 was increased in a 
colorectal cancer cell line, the p53 pathway, which involves apoptosis, was also altered.  This 
indicates that miR-211 may have an influence on the regulation of apoptosis
75
.  Although this 
may imply a role in overall process of cancer progression, further investigation is needed to 
determine if miR-211 alterations are required for tumor progression.   
In addition, let-7a was found to be downregulated in spitzoid melanomas when compared 
to benign nevi, benign Spitz tumors, and atypical Spitz tumors.  Let-7a was also found to be 
dysregulated in melanoma in publications by Philippidou et al.
 12
 and Schultz et al.
 103
.  The 
dysregulation of let-7a has been found to be involved in many different types of cancer, 
including breast
77,78,79
, lung
80
, gastric
81,82,83,84
, prostate
85
, renal
86
, colorectal 
87,88
, and ovarian
89
 
cancers.  Let-7a is suspected to regulate many different targets, including the RAS 
90,91
 and 
MYC
86,92
 mRNAs.  The respective proteins of these target genes are both involved in the 
regulation of apoptosis
93,94
.  The downregulation of let-7a would allow for increased translation 
of its targets, RAS and MYC.  It is thought that involvement of let-7a in cancer is not specific to a 
particular tissue type, but that it is involved in the overall processes of cell proliferation, 
apoptosis, and the cell cycle. 
A factor that may alter microRNA expression in the tissues types, benign nevi, benign 
Spitz tumors, and spitzoid melanomas is the V600E BRAF mutation.  The protein of the BRAF 
gene functions to phosphorylate and activate the MAP Kinase pathway, which influences cell 
proliferation, cell differentiation, and transcriptional regulation.  The V600E BRAF mutation 
causes a missense mutation in the translational code of the protein, substituting a glutamic acid 
for a valine.  The BRAF mutation is found to be in several cancers, including non-small cell 
lung, colorectal, papillary thyroid, and ovarian cancers
105
.  Fullen et al. found the V600E BRAF 
  Clark J.R. 
19 
 
mutation to be present in 82% of the benign tissues and in 33% of primary cutaneous melanomas 
studied.  In addition, Fullen et al. found the mutation in 21% of the 28 benign Spitz tumors and 
15% of the 12 spitzoid melanomas studied.  However, the mutation has not been found in 
atypical Spitz tumors
106
.  Evidence by Caramuta et al. suggests that the BRAF mutation may 
have an effect on the transcriptional regulation of microRNAs
107
.  Therefore, the BRAF mutation 
may alter the transcriptional regulation of microRNAs in hyper-pigmented lesions.  As a result, 
the presence of this mutation may be a confounding factor in the correlation of microRNA 
expression and malignancy.   
In this investigation, there were some discrepancies in the results of microRNA 
expression as compared to previous studies.  For instance, miR-23b was found to be upregulated 
in benign Spitz tumors and in atypical Spitz tumors when compared to benign nevi.  Conversely, 
miR-23b was found to be downregulated in publications by Philippidou et al.
 12 
and Jukic et al
101
, 
when comparing melanoma samples to benign nevi.  In this study, miR-34a was observed to be 
upregulated in benign Spitz tumors as compared to benign nevi, in spitzoid melanomas as 
compared to benign nevi, and in spitzoid melanomas as compared to atypical Spitz tumors.  
Conversely, miR-34a was found to be downregulated by Satzger et al. when comparing 
melanoma to benign nevi
99
.  In this study, miR-148b was found to be upregulated in spitzoid 
melanomas as compared to benign nevi, benign Spitz tumors, and atypical Spitz tumors.  
Conversely, miR-148b was found to be downregulated in publications by Philippidou et al.
 12
 
and Mueller et al.
 5
 when comparing melanoma to benign nevi.  Although the results disagree 
with the direction of dysregulation that was previously established, the expression of the 
microRNAs seems to be consistent across the spectrum of tissue types within this study. In 
addition, only melanoma and benign nevi were compared in the previous studies reviewed.  
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These studies exclude melanoma, specific to spitzoid type, benign Spitz tumors, and the atypical 
Spitz tumors, which are the main focus of this study.  Other reasons that could account for the 
discrepancy are the differing techniques, methods, or statistical analysis used, variation upon 
interpretation of results, or error on the part of the investigator.   
Another discrepancy is in the lack of significance found in the expression comparisons of 
miR-21, miR-17-5p, and miR-200c in the melanoma types studied.  MiR-21 was found to be 
significantly upregulated in malignant melanoma as compared to benign nevi by Grignol et al.
7 
and Jiang et al.
 98
.  MiR-17-5p was found to be significantly upregulated in malignant melanoma 
as compared to benign nevi by Mueller et al.
 5
 and Greenberg et al.
 97
.  MiR-200c was found to 
be downregulated in malignant melanoma as compared to benign nevi by Philippidou et al.
 12
, 
Xu et al.
 96
, and Elson Schwab et al.
 95
.  The lack of consistency between this investigation and 
other studies may be accounted for by the limited number of samples available for this study, 
specifically spitzoid melanomas.  Also, this investigation looked specifically at melanoma of the 
spitzoid type, which may have different microRNA expression compared to that of all melanoma 
types combined. 
This study found a number of microRNAs to be significantly dysregulated in 
comparisons between benign nevi, benign Spitz tumors, atypical Spitz tumors, and spitzoid 
melanomas.  These results may develop a signature that could distinguish one tissue type from 
another tissue type in a patient sample.  However, as there were a limited number of tissue 
samples available for use, further investigation measuring the microRNAs in more samples of 
these melanocytic lesions is necessary to establish a definitive, indisputable signature for these 
spitzoid melanocytic lesions.  Specifically, spitzoid melanomas should be further investigated in 
greater number than what was attained in this study.  Future studies should also include applying 
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the signature to patient samples, verifying it with previously established histopathological 
methods, and following the patient outcomes.  The development of a microRNA signature in 
these spitzoid melanocytic lesions may lead to improved accuracy in providing a diagnosis, 
prognosis, and treatment plan for patients with these spitzoid melanocytic lesions.  
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